Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies.

Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ.

Bone Marrow Transplant. 1996 Aug;18(2):347-53.

PMID:
8864445
2.

Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.

Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA.

J Clin Virol. 1999 Aug;13(3):149-59.

PMID:
10443791
3.

Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.

Bone Marrow Transplant. 1996 Apr;17(4):589-93.

PMID:
8722360
4.

Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.

Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ.

Transplantation. 2002 Jul 15;74(1):49-54.

PMID:
12134098
5.

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.

Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N, Childs R, Barrett AJ.

Bone Marrow Transplant. 2002 Aug;30(4):235-42.

6.

Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.

Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.

Transpl Infect Dis. 2007 Dec;9(4):286-94.

PMID:
17511819
7.

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.

Trenschel R, Ross S, Hüsing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW, Runde V.

Bone Marrow Transplant. 2000 Mar;25(6):665-72.

8.

CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.

Bacigalupo A, Tedone E, Sanna MA, Moro F, Van Lint MT, Grazi G, Balestreri M, Frassoni F, Occhini D, Gualandi F, et al.

Haematologica. 1992 Nov-Dec;77(6):507-13.

PMID:
1337746
9.

Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.

de Medeiros CR, Moreira VA, Pasquini R.

Bone Marrow Transplant. 2000 Aug;26(4):443-4.

10.

Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.

Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al.

Bone Marrow Transplant. 1994 Apr;13(4):461-4.

PMID:
8019472
11.

Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.

Matsunaga T, Sakamaki S, Ishigaki S, Kohda K, Takeda M, Katoh J, Kuroda H, Hirayama Y, Kusakabe T, Akiyama T, Kuga T, Niitsu Y, Masaoka T, Sagawa T, Matsumoto Y.

Int J Hematol. 1999 Feb;69(2):105-11.

PMID:
10071460
12.
13.

In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.

Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U, Heimpel H, Arnold R, Mertens T.

Bone Marrow Transplant. 1995 Mar;15(3):387-93.

PMID:
7599563
14.
15.

CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.

Bacigalupo A, Tedone E, Van Lint MT, Trespi G, Lonngren M, Sanna MA, Moro F, Frassoni F, Occhini D, Gualandi F, et al.

Bone Marrow Transplant. 1994 Jun;13(6):783-8.

PMID:
7920315
16.

Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.

Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ.

Biol Blood Marrow Transplant. 2004 Jan;10(1):49-57.

17.

Interstitial pneumonitis in T cell-depleted bone marrow transplantation.

Breuer R, Or R, Lijovetzky G, Naparstek E, Engelhard D, Lafair J, Weshler Z, Slavin S.

Bone Marrow Transplant. 1988 Nov;3(6):625-30.

PMID:
2850831
18.
20.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

Supplemental Content

Support Center